KRAS Q61 NSCLC: When Alleles Matter.

Abstract

A recent article provides the largest characterization to date of KRAS Q61-mutant NSCLC. The findings reveal clinically relevant differences between Q61 alleles and highlight the importance of interpreting KRAS mutations within their genomic context. As RAS-directed therapies evolve, understanding this heterogeneity becomes increasingly relevant for patient stratification and therapeutic development.